CEL-SCI, Saudi Amarox Sign Multikine Deal
Analysis based on 6 articles · First reported Jun 12, 2026 · Last updated Jun 24, 2026
The strategic agreement between CEL-SCI Corporation and Saudi Amarox is expected to positively impact CEL-SCI Corporation's stock price due to expanded market access for Multikine in a rapidly growing healthcare market. It also highlights Saudi Arabia's increasing importance as a hub for biotechnology investment, potentially attracting further foreign direct investment into its healthcare sector.
CEL-SCI Corporation and Saudi Amarox formally signed a strategic agreement at the Cape Town International Convention Centre 2026 for the commercialization and distribution of Multikine, a cancer immunotherapy, in Saudi Arabia. This collaboration is a significant step towards making Multikine available to patients in Saudi Arabia, a country making substantial investments in its biotechnology sector under its Saudi Vision 2030 strategy. The agreement includes a 50%/50% revenue share for Multikine sales upon receipt of Breakthrough Medicine Designation, with Saudi Amarox acting as the local regulatory representative and exclusive commercial distributor. Saudi Amarox also has the option to expand the agreement to other Gulf Cooperation Council countries. This partnership underscores the growing U.S.-Saudi cooperation in healthcare innovation and oncology.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard